ESC 365 - Use and safety of sodium-glucose cotransporter 2 inhibitors in a prospective cohort of patients with transthyretin amyloid cardiomyopathy.

HFA Premium Access

Use and safety of sodium-glucose cotransporter 2 inhibitors in a prospective cohort of patients with transthyretin amyloid cardiomyopathy.

Session: Novelties in amyloid cardiomyopathy

Topic: Clinical

Speaker: Doctor M. Maccallini (Milan, IT)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Doctor Marta Maccallini

Humanitas Research Hospital, Milan (Italy)

0 follower

3 more presentations in this session

Phenotypic expression and outcomes of cardiomyopathy caused by titin truncating variants: translational insights

Speaker: Doctor M. Perotto (Trieste, IT)

Biohumoral and echocardiographic correlates of tafamidis treatment in transthyretin cardiac amyloidosis

Speaker: Doctor V. Castiglione (Pisa, IT) Doctor G. Vergaro (Pisa, IT)

Prognostic value of tricuspid annular plane systolic excursion/systolic pulmonary artery pressure (TAPSE/SPAP) ratio in amyloid cardiomyopathy

Speaker: Doctor M. Maccallini (Milan, IT)

Access the full session

Novelties in amyloid cardiomyopathy

Speakers: Doctor M. Maccallini, Doctor M. Perotto, Doctor V. Castiglione, Doctor G. Vergaro, Doctor M. Maccallini

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources